Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
-
-
Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
-
Thermo Fisher announced plans to expand sterile filling capacity for therapies and vaccines with new facility in Singapore
On Oct. 14, 2020, Thermo Fisher Scientific announced plans to develop two new sterile filling lines in Singapore…
-
COVID-19 vaccine with Dynavaxﾒs CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
-
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
-
Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
-
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
-
Pfizer Canada and BioNTech initiated rolling submission to Health Canada for SARS-CoV-2 vaccine candidate
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
-
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
-
Biotechnology | Infectious Disease | Influenza | Measles | Plague | Polio | Vaccine
DARPA awarded Moderna $56 Million to enable small-scale, rapid mobile manufacturing of vaccines and therapeutics
On Oct. 8, 2020, Moderna announced an agreement for a commitment of up to $56 million from the…
-
Johnson & Johnson announced EC approval of agreement to supply 200 million doses of COVID-19 vaccine candidate
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
-
Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
-
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
-
Kindred Biosciences announced expansion of Manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates
On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of…
-
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services (HHS) announced funding of a patch…
-
BioNTech and Pfizer initiated a rolling submission to EMA for SARS-CoV-2 vaccine candidate BNT162b2
On Oct. 6, 2020, Pfizer and BioNTech announced initiation of a rolling submission to the European Medicines Agency…
-
Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAP vaccine patch
On Oct. 5, 2020, Vaxxas announced a $22 million United States government award to support the deployment of…
-
COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
On Oct. 2, 2020, AstraZeneca announced the phase I/II clinical trial for the COVID-19 vaccine AZD1222 had resumed…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Pharmaceutical | Therapeutics | Vaccine | WHO
WHO welcomed $90 million contribution from Kingdom of Saudi Arabia to support COVID-19 global response
On Oct. 2, 2020, the World Health Organization (WHO) and the Kingdom of Saudi Arabia signed a contribution…
-
Amyris delivered sustainable alternative to shark squalene adjuvant enabling vaccines with no sharks killed
On Oct. 1, 2020, Amyris announced that it has begun delivering samples to pharmaceutical companies of a sustainable…
-
BioNTech and Pfizer announced Nature publication of German phase 1/2 study data from mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2…
-
Investigational COVID-19 vaccine well tolerated and generated iImmune response in older adults
On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases announced that a phase 1 trial…
-
Serum Institute to produce additional 100 million Covid-19 vaccine doses for India and low-and middle-income countries
On Sept. 29, 2020, a further collaboration among the Serum Institute of India (SII), Gavi and the Bill…
-
New look at COVID-19 cases does not support link between BCG vaccination and lower mortality
On Sept. 29, 2020, In a new Letter, published in PNAS, researchers at La Jolla Institute for Immunology…
-
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…
-
Biotechnology | NIH | Vaccine
COVID-19 vaccine generated immune response in older adults
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
-
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
-
ViroVax licensed adjuvant to be used in India’s first COVID-19 vaccine in human trials
On Sept. 28 2020, ViroVax announced that it had licensed its adjuvant, Alhydroxiquim-II, to Bharat Biotech International, an…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | NIH | Vaccine
INOVIO reported FDA partial clinical hold for planned phase 2/3 trial of COVID-19 vaccine candidate INO-4800
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
-
CDC’s ACIP recommended routine vaccination with a quadrivalent meningococcal conjugate vaccine for adolescents aged 11 or 12 years, with a booster dose at age 16 years.
On Sept. 25, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with a quadrivalent meningococcal…
